Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
P&G/Gillette management
Gillette Global Oral Care President Bruce Cleverly, who headed Gillette's Oral-B line, will assume the post of president of global oral care following the completion of Procter & Gamble's acquisition of Gillette, P&G announces July 19. The $57 bil. merger was approved by the European Commission July 15 and is on track to close in the fall (1"The Tan Sheet" July 18, 2005, In Brief). Other management changes following the deal's completion include the appointment of Charlie Pierce to president, P&G Oral Care. Pierce currently serves as president of P&G Global Oral Care. Additionally, Charles Bergh, P&G president on special assignment, will assume the position of president on special assignment - blades and razors. Mary Ann Pesce, president of Gillette global personal care, will be elected president - new business development...
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.
• By
The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.
• By
The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.